Skip to main content
Quest Diagnostics

Biomarker Testing in Alzheimer’s Disease

Learning Objectives:

  -  Gain understanding of dementia and the laboratory tests used fo help evaluate

     these patients

  -  Know how amyloid, tau and neurodegeneration participate in Alzheimer's

     Disease

  -  Gain understanding of how biomakers and PET are used to evaluate Alzheimer's

     Disease

 

Presented by: Michael K. Racke, MD, Medical Director of Neurology, Quest Diagnostics  

 

Moderated by: Gabriele Olla, Dir Product Management , Neurology, Quest Diagnostics

Date:
Sep 29, 2021
Location:
Biomarker Testing in Alzheimer's Disease on-demand webinar
Presenter(s):
Michael K. Racke, MD
Moderator(s):
Gabriele Olla

Related content

On-Demand Webinar
Revolutionizing Alzheimer’s Disease Clinical Trials Using a Blood-Based Diagnostic Test for Participant Identification
On-Demand Webinar
Assessing Alzheimer's Disease Risk in Primary Care Settings
Audio Podcast
Alzheimer’s disease: A new generation of screenings and therapies on the horizon
Audio Podcast
Patient-minded Neurology
Publication
The small HDL particle hypothesis of Alzheimer's disease
On-Demand Webinar
Revolutionizing Alzheimer’s Disease Clinical Trials Using a Blood-Based Diagnostic Test for Participant Identification

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2025 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.